Inhibikase Therapeutics Stock News

Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Analyst Recommendations This is a summary of recent ratings and price targets for Inhibikase Therapeutics []

Inhibikase Therapeutics (NYSE: IKT) is one of 237 publicly-traded companies in the Biological products, except diagnostic industry, but how does it compare to its rivals? We will compare Inhibikase Therapeutics to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership. Valuation & Earnings This table compares []

In last trading session, Inhibikase Therapeutics Inc. (NASDAQ:IKT) saw 0.55 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $1.65 trading at -$0.12 or -6.78% at ring of the bell on the day assigns it a market valuation of $41.25M. That closing price of IKTs stock is Inhibikase Therapeutics Inc. (NASDAQ:IKT) Has Recovered -2.42% So Far, But Another -627.27% Loss Cannot Be Ruled Out Read More »

The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) increased by over 10% pre-market today. This is why it happened.

ATLANTA, Oct. 19, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di

The stock price of Inhibikase Therapeutics, Inc. (Nasdaq: IKT) increased over 5% pre-market today. This is why it happened.

ATLANTA, Oct. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of

ATLANTA, Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of

ATLANTA, Aug. 16, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di

ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of

ATLANTA, June 18, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di

The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) fell by over 25% pre-market. This is why it happened.

ATLANTA, June 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di

ATLANTA, May 17, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's dis

ATLANTA, April 21, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di